Akcea nets $133.7mm via IPO
After filing back in March, Ionis Pharmaceutical Inc.'s Akcea Therapeutics Inc. netted $133.7mm through an upsized initial public offering of 17.9mm common shares (including the overallotment) at $8 each. It planned to sell 9.6mm shares between $12 and $14. Ionis purchased 3.1mm shares in the IPO and will now own 68.3% of Akcea.
- Antisense, Oligonucleotides
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com